Alto Neuroscience Inc.

ANRO | NYSE

Price Alert Chart Builder DCF Calculator

$30.71

+$0.08 (+0.26%)

Sep 22, 2026, 9:30 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.26%

(1D)

Rating

Updated: Aug 25, 2026

29.5

Fundamentals Weak

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $1.08B

1D Range

30.71 30.71

52W Range

3.77 37.48

Valuation (TTM)

PE -12.35

PB 4.90

EV/EBITDA -10.29

Valuation (NTM)

Forward PE N/A

Forward PEG -1.21

Price Target $38

Cash Flow

FCF Yield -6.4%

SBC Adj. FCF Yield -7.2%

SBC Impact -12.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -14.1% | N/A

FCF 3Y | 5Y -23.1% | N/A

Returns

ROA -33.2%

ROE -46.5%

ROIC 18.4%

Financial Health

Net Cash

$236.68M

Current Ratio 14.85

Interest Coverage 19.66

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an inve...

Sector Healthcare

Industry Biotechnology

Employees 68

IPO Date Feb 1, 2024

Website www.altoneuroscience.com

Fiscal Year January - December

Full Company Profile

Latest News

13 days ago · businesswire.com

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time.

26 days ago · businesswire.com

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto's founder, chief executive officer and c.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$36.50

Upside

+18.85%

Buy (7)

Hold (1)

Sell (0)

Analyst Details ➞